N/A N=852 Veterans Experiences Using Secure Messaging
Telemedicine
Primary: Usability of Secure Messaging — 21; 10; 2; 30 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=70 Effect of Omega 3 Fatty Acids on Oxidative Stress in HIV Seropositive Patients
HIV/AIDS
Primary: Change on Malondialdehyde After Treatment With Omega 3 Acids for 6 Months Compared With Placebo in HIV Seropositive Patients — -1.18; -0.9 nM/mg protein
Phase 2 N=14 Thyroid and Glucose and Energy Metabolism
Thyroid Diseases
Primary: Insulin-mediated Glucose Disposal Rate at Levothyroxine Treatment Phase — 7.26 mg/kg/min
Phase 2 N=8 Cryotherapy and GM-CSF in Treating Patients With Lung Metastases or Primary Lung Cancer
Kidney Cancer · Lung Cancer · Metastatic Cancer
Primary: Immunologic Response as Measured by ELISPOT Assay and Flow Cytometry — 1; 3; 2 Participants
N/A N=1,533 The Possible Correlations Between the Genes Related to Pain Sensation and the Pain Sensitivity in the General Population
Pain · Surgery
Primary: Preoperative Pressure Pain Threshold (PPT) — 2.33; 3.24 kg/cm2
N/A N=20 Measurement of Bispectral Index and Awareness in Patients Undergoing Electrophysiology Studies With Isoproterenol
Intraoperative Awareness
Primary: Number of Participants With an Increase in BIS Readings During Steady State — 19 participants
Phase 2 N=52 Feasibility Study of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-cell Malignancies
Indolent or Intermediate Grade B-cell Malignancy
Primary: Incidence of Grade III and IV Hypersensitivity Reactions — 0 percentage of patients
Phase 2 N=3 Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer
Adenocarcinoma of the Colon · Adenocarcinoma of the Rectum · Recurrent Colon Cancer
Primary: Recommended Phase II Dose of Pertuzumab When Administered in Combination With Cetuximab (Phase I) — NA
Phase 2 N=30 SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Adult Lymphocyte Depletion Hodgkin Lymphoma · Adult Lymphocyte Predominant Hodgkin Lymphoma · Adult Mixed Cellularity Hodgkin Lymphoma
Primary: Number of Participants With Overall Response (OR) — 15; 4 participants
N/A N=40 Cryotherapy in Treating Patients With Primary Lung Cancer or Lung Metastases That Cannot Be Removed By Surgery
Lung Cancer · Metastatic Cancer
Primary: Local Failure Rates by CT Scan — 15 % of participants
Phase 2 N=62 Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer
Endometrial Adenocarcinoma · Endometrial Adenosquamous Cell Carcinoma · Endometrial Clear Cell Carcinoma
Primary: Objective Clinical Response Rate — 13.8; 4.0 percentage of patients with response
N/A N=109 Bacterial Contamination of Healthcare Worker Uniforms
Bacterial Contamination of Healthcare Worker Uniforms
Primary: Total Bacterial Contamination of Healthcare Worker Uniform With Antimicrobial Properties Compared to Standard Healthcare Worker Uniform After an 8-hour Workday. — 41…
Phase 3 N=80 PIE II: Pharmacological Intervention in the Elderly II
Diastolic Heart Failure · Heart Failure, Congestive
Primary: Exercise Intolerance — 13.5; 13.3; 13.6; 13.5 ml/kg/min
Early Phase 1 N=95 Melatonin Versus Placebo in Breast Cancer
Breast Cancer
Primary: Absolute Plasma Estradiol Levels After 4 Month Course of Melatonin or Placebo — 4.59; 3.39 pg/ml — p=<0.05
Phase 2 N=122 A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.
Idiopathic Thrombocytopenic Purpura
Primary: Percentage of Participants Achieving a Complete Hematological Response (CR) or Confirmed Partial Hematological Response (PR) — 43.5 percentage of participants